Michael R Ruff
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2019First federal award
$9.5MFederal grants as PI10 awards
3Patents grantedLatest Oct 14, 2025
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
10 awards · $9.5M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| May 28, 2025 | NIH | SBIR Phase II A Synapse-Protecting Small Peptide to Treat a-Syn/Tau Mixed Proteinopathies in Alzheimer's Disease Related Dementias (ADRD) | $1.1M | CREATIVE BIO-PEPTIDES, INC. |
| Jul 31, 2024 | NIH | SBIR Phase II A Synapse-Protecting Small Peptide to Treat a-Syn/Tau Mixed Proteinopathies in Alzheimer's Disease Related Dementias (ADRD) | $1.4M | CREATIVE BIO-PEPTIDES, INC. |
| Jul 9, 2024 | NIH | SBIR Phase I PET Imaging to Evaluate a Novel Chemokine Antagonist to Protect Synapses in ADRD | $175K | CREATIVE BIO-PEPTIDES, INC. |
| Sep 25, 2023 | NIH | SBIR Phase I PET Imaging to Evaluate a Novel Chemokine Antagonist to Protect Synapses in ADRD | $325K | CREATIVE BIO-PEPTIDES, INC. |
| Aug 19, 2022 | NIH | SBIR Phase II Development of a Novel Chemokine Receptor Antagonist as a Treatment for Opioid Use Disorder | $1.1M | CREATIVE BIO-PEPTIDES, INC. |
| Sep 22, 2021 | NIH | SBIR Phase II Development of a Novel Chemokine Receptor Antagonist as a Treatment for Opioid Use Disorder | $1.2M | CREATIVE BIO-PEPTIDES, INC. |
| Sep 9, 2021 | NIH | SBIR Phase II Development of a Novel Chemokine Receptor Antagonist Peptide as a Non-Opioid Treatment for Relief of Chronic Pain | $3.0M | CREATIVE BIO-PEPTIDES, INC. |
| Sep 6, 2021 | NIH | SBIR Phase I Optimization of a Chemokine Receptor Antagonist Peptide as a Synapse Protecting Treatment for Neurodegeneration in Alzheimer's Disease | $500K | CREATIVE BIO-PEPTIDES, INC. |
| Sep 15, 2020 | NIH | SBIR Phase I Development of a Novel Chemokine Receptor Antagonist Peptide as a Synapse Protecting Treatment for Neurodegeneration in Alzheimer's Disease | $449K | CREATIVE BIO-PEPTIDES, INC. |
| Sep 18, 2019 | NIH | SBIR Phase I A Novel Chemokine Receptor Antagonist to Block Opioid Reinforcement, Relapse and Physical Dependence | $322K | CREATIVE BIO-PEPTIDES, INC. |
4 patents as inventor
- US 12257283CREATIVE BIO-PEPTIDES, INC.Mar 25, 2025
- US RE50563CREATIVE BIO-PEPTIDES, INC.Sep 2, 2025
- US RE50630CREATIVE BIO-PEPTIDES, INC.Oct 14, 2025
- US CREATIVE BIO-PEPTIDES, INC.—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#68
Awards as PI#128
Patents#63
Companies
- CREATIVE BIO-PEPTIDES, INC.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.